ADMA Biologics (NASDAQ:ADMA) Shares Up 6.1% – Here’s What Happened

ADMA Biologics, Inc. (NASDAQ:ADMA) shares shot up 6.1% on Wednesday . The stock traded as high as $19.91 and last traded at $19.85. 2,397,523 shares were traded during trading, a decline of 28% from the average session volume of 3,320,496 shares. The stock had previously closed at $18.71.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Trading Up 0.8 %

The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a fifty day moving average of $16.74 and a 200-day moving average of $18.01. The firm has a market capitalization of $4.68 billion, a PE ratio of 70.71 and a beta of 0.60.

Hedge Funds Weigh In On ADMA Biologics

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in ADMA Biologics by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock valued at $312,109,000 after buying an additional 80,302 shares in the last quarter. State Street Corp raised its holdings in ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after buying an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC raised its holdings in ADMA Biologics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock valued at $93,187,000 after buying an additional 50,399 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of ADMA Biologics by 16.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after purchasing an additional 643,661 shares during the period. Finally, Renaissance Technologies LLC grew its position in ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock worth $64,654,000 after buying an additional 102,692 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.